JIM E RIVIERE
Veterinary in Raleigh, NC

6066091, May 23, 2000

Feb 23, 1998

9/027670

Jim E. Riviere - Raleigh NC
Tomas Martin-Jimenez - Cary NC
Ronald E. Baynes - Cary NC
Arthur L. Craigmill - Oregon House CA

North Carolina State University - Raleigh NC

A61N 500

600300

A first aspect of the invention is a method of estimating a withdrawal interval for an adjusted dose of a compound from a prior withdrawal time for a corresponding prior dose of that compound, corresponding half-life data and a tolerance concentration, for a tissue of interest. The method comprises selecting an adjusted dose for the compound for which a withdrawal interval is to be determined, and extrapolating a withdrawal interval from (a) the prior dose, (b) the prior withdrawal time, (c) the half-life data, and (d) the tolerance concentration. The process is useful for determining a withdrawal interval for an extralabel (i. e. , non-approved) use of a drug in the same or a different jurisdiction for which a previous use has been approved, and can be used to determine an appropriate withdrawl interval for a drug in food products exported from one jurisdiction to another. Data processing systems and computer program products for carrying out the foregoing are also disclosed.

7517693, Apr 14, 2009

Mar 5, 2003

10/382209

Jim E. Riviere - Raleigh NC, US
Ronald E. Baynes - Garner NC, US

North Carolina State University - Raleigh NC

G01N 21/00, G01N 21/75, G01N 21/77

436164, 422 681, 422101, 436169, 73 38, 73 6447

A method of determining a molecular descriptor of absorption for a candidate compound is disclosed. The method includes: providing a test solution comprising one or more candidate compounds; contacting the test solution with a simulated biological membrane to partition the one or more candidate compounds into the membrane detecting the presence or amount of the one or more candidate compound in the membrane at one or more permeation times; and determining a molecular descriptor of absorption using the presence or amount of the one or more candidate compound in the membrane at the one or more permeation times. In one aspect the invention provides a skin-imitating membrane, and one or more percutaneous absorption parameters are determined. In another aspect the membrane is disposed on a fiber. In another aspect the test solution is contacted with two or more simulated biological membranes to partition the one or more candidate compounds into the membranes.

5540654, Jul 30, 1996

Sep 2, 1994

8/300054

Jim E. Riviere - Raleigh NC
Richard A. Rogers - Garner NC

North Carolina State University - Raleigh NC

A61N 130

604 20

The iontophoretic device of the present invention comprises (a) a source for providing an electrical signal, (b) an electrode mounting block having a plurality of separate openings formed therein in spaced-apart relation from one another, with each of the openings configured to receive an iontophoresis electrode, (c) a plurality of iontophoresis electrodes electrically connected to the source and capable of transmitting electrical signal, each of the iontophoresis electrodes having a skin contact surface and each of the iontophoresis electrodes being received in one of the openings formed in the electrode mounting block, (d) a signal distribution network electrically connected to both the source and each of the plurality of electrodes and configured for distributing a electrical signal to each of the plurality of electrodes, and (e) a receiver connected to the source for accepting electrical signal transmitted by the plurality of electrodes, with the receiver of sufficient capacity to simultaneously accept electrical signal transmitted by each of the plurality of electrodes.

5302172, Apr 12, 1994

Feb 8, 1991

7/653202

Burton H. Sage - Raleigh NC
Jim E. Riviere - Raleigh NC

North Carolina State University - NC
Becton, Dickinson and Company - NJ

A61N 130

604 20

The invention discloses methods and compositions for enhanced iontophoretic delivery of active agents. The compositions are pharmaceutically acceptable compositions for iontophoretic delivery comprising a delivery enhancing amount of a vasodilator and active agent. Methods comprise adding a delivery enhancing amount of a vasodilator to an active agent and delivering by iontophoresis.

5620416, Apr 15, 1997

Jun 7, 1995

8/473318

Jim E. Riviere - Raleigh NC

North Carolina State University - Raleigh NC

A61M 3100

604 49

The present invention relates to the simultaneous administration of topical agents and systemic active agents to treat diseases of the skin and surrounding tissues, wherein the topical drug is applied to a treatment area and affects the concentration or activity of the systemic drug in that area.

5334138, Aug 2, 1994

Feb 8, 1991

7/653204

Burton H. Sage - Raleigh NC
Jim E. Riviere - Raleigh NC

North Carolina State University - Raleigh NC
Becton Dickinson and Company - Franklin Lakes NJ

A61N 130

604 20

The invention discloses methods and compositions for enhanced skin concentration of iontophoretic delivered active agents. The compositions are pharmaceutically acceptable compositions for iontophoretic delivery which comprise a skin concentration enhancing amount of a vasoconstrictor and active agent. Methods comprise adding a skin concentration enhancing amount of a vasoconstrictor to an active agent and delivering by iontophoresis.